Dr. Feld graduated from medical school at the University of Toronto in 1997 and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis. He completed a clinical research fellowship in hepatology and then spent 4 years doing clinical and laboratory research in the Liver Diseases Branch of the National Institutes of Health. He received a Masters of Public Health with a focus on Infectious Diseases as a Sommer Scholar from Johns Hopkins University and has worked extensively abroad, maintaining a strong interest in International Health. Curently, Dr. Feld is clinician-scientist based at the Toronto Western Hospital Liver Clinic and the McLaughlin-Rotman Centre for Global Health.
Dr. Felds research focuses on understanding treatment non-response in hepatitis C and more broadly on understanding the antiviral immune response and developing new strategies for the treatment of viral hepatitis.
Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy.
Clin Infect Dis. 2019 Nov 02;:
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
J Hepatol. 2019 Oct 23;:
J Hepatol. 2019 Oct 21;:
Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial.
Lancet Respir Med. 2019 Oct 09;:
Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis.
Hepatol Commun. 2019 Oct;3(10):1388-1399
The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach.
Liver Int. 2019 Sep 11;:
Viruses. 2019 Sep 06;11(9):
Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
Gut. 2019 Aug 28;:
Gastroenterol Hepatol (N Y). 2019 Jun;15(6):303-306
Senior Scientist, Toronto General Hospital Research Institute (TGHRI)
Scientist, Sandra Rotman Centre for Global Health, Toronto, Ontario, Canada
Research Director, Gastroenterology, Medicine/University of Toronto, Francis Family Liver Clinic - Toronto Western Hospital, Toronto, Ontario, Canada
Associate Professor of Medicine, University of Toronto, Toronto, Ontario, Canada